Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
20.99
-0.07 (-0.33%)
Streaming Delayed Price
Updated: 12:28 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Uncertain Times
December 15, 2021
The UK inflation rate last month was 5.1%, not a good omen.
Via
Talk Markets
The Sunday File for Nov. 21
November 21, 2021
Good news and bad - making up for the short week by getting a Sunday start.
Via
Talk Markets
3 No-Brainer Biotech Stocks to Buy in November
November 04, 2021
Here are three Motley Fool contributors' top picks.
Via
The Motley Fool
Analyst Ratings For Exelixis
November 03, 2021
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
July 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...
Via
Benzinga
Exposures
COVID-19
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 03, 2021
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript
November 02, 2021
EXEL earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis: Q3 Earnings Insights
November 02, 2021
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis...
Via
Benzinga
Exelixis Earnings Perspective: Return On Capital Employed
November 02, 2021
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
November 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...
Via
Benzinga
Exposures
COVID-19
Here's My Top Value Stock To Buy Right Now
November 01, 2021
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
Via
Talk Markets
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Down 76%: Is Cortexyme Stock a Bargain?
October 28, 2021
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
Via
The Motley Fool
EVP And Scientific Strategy Cso Of Exelixis Trades $1.3M In Company Stock
October 18, 2021
Peter Lamb, EVP And Scientific Strategy Cso at Exelixis (NASDAQ:EXEL), made a large buy and sell of company shares on October 15, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
More Chinese Trouble
October 14, 2021
A day after the consumer price rise there was another price rise for producer markets.
Via
Talk Markets
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
September 20, 2021
The FDA has approved Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) for thyroid cancer in patients aged 12 years and older. The approval covers...
Via
Benzinga
Exposures
Product Safety
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street; Crude Oil Down 2%
September 20, 2021
Pre-open movers U.S. stock futures traded sharply lower in early pre-market trade after recording losses in the previous session. Investors are awaiting earnings results from...
Via
Benzinga
Exposures
Fossil Fuels
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
October 07, 2021
Upgrades For State Street Corporation (NYSE:
Via
Benzinga
Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery
September 16, 2021
Exelixis Inc (NASDAQ: EXEL) has announced results demonstrating efficacy benefits of Cabometyx (cabozantinib) in patients with previously untreated advanced renal...
Via
Benzinga
2 Top Biotech Stocks to Buy Right Now
September 11, 2021
Both have underperformed the market recently. And both are primed for a comeback.
Via
The Motley Fool
Is Exelixis Stock a Buy?
September 02, 2021
This biotech stock is down, but it's not out just yet.
Via
The Motley Fool
Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer
August 26, 2021
Exelixis Inc's (NASDAQ: EXEL) collaborating partner Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Ono Pharmaceutical Co Ltd have received...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 17, 2021
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9...
Via
Benzinga
Exelixis, Invenra Expand Oncology Pact
August 16, 2021
Exelixis Inc (NASDAQ: EXEL) and Invenra have expanded their discovery and licensing collaboration to include 20 additional oncology targets. The augmented...
Via
Benzinga
Exelixis, inc (EXEL) Q2 2021 Earnings Call Transcript
August 06, 2021
EXEL earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Recap: Exelixis Q2 Earnings
August 05, 2021
Shares of Exelixis (NASDAQ:EXEL) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 48.00% year over year...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
August 05, 2021
Gainers Sensus Healthcare (NASDAQ:SRTS) ...
Via
Benzinga
Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid Cancer
August 05, 2021
The FDA has accepted Exelixis Inc's (NASDAQ: EXEL) supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.